HUMA (Humacyte) OCF Margin %: -5,071.52% (As of Mar. 2026)

What is Humacyte OCF Margin %?

Humacyte HUMA -2.68% 21 OCF Margin % is -5,071.52% as of Mar. 2026. GuruFocus rates HUMA with a GF Score™ of 21/100. The stock has 6 warning signs investors should review. Among 960 Biotechnology companies, Humacyte ranks worse than 91.25% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Humacyte's Cash Flow from Operations for the three months ended in Mar. 2026 was $-25.10 Mil. Humacyte's Revenue for the three months ended in Mar. 2026 was $0.50 Mil. Therefore, Humacyte's OCF Margin % for the quarter that ended in Mar. 2026 was -5,071.52%.

As of today, Humacyte's current OCF Yield % is -55.29%.

The historical rank and industry rank for Humacyte's OCF Margin % or its related term are showing as below:

HUMA' s OCF Margin % Range Over the Past 10 Years
Min: -5154.17 Med: -5154.17 Max: -5154.17
Current: -5036.95

During the past 6 years, the highest OCF Margin % of Humacyte was -5154.17%. The lowest was -5154.17%. And the median was -5154.17%.

HUMA's OCF Margin % is ranked worse than
91.25% of 960 companies
in the Biotechnology industry
Industry Median: -68.59 vs HUMA: -5036.95

Humacyte OCF Margin % Related Terms

Humacyte OCF Margin % Historical Data

* Premium members only.

The historical data trend for Humacyte's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Humacyte OCF Margin % Chart

Humacyte Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

OCF Margin %

Get a 7-Day Free Trial

0.00

-5,154.17

Humacyte Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
OCF Margin %	Get a 7-Day Free Trial															-5,532.11	-8,775.08	-3,174.50	-5,594.00	-5,071.52

HUMA vs ZNTL, AVXL, ELDN: OCF Margin % Comparison

For the Biotechnology subindustry, Humacyte's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Humacyte OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Humacyte's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Humacyte's OCF Margin % falls into.

Save Embed

21GF Score

Humacyte Inc HUMA

OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Humacyte OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Humacyte's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin	=	Cash Flow from Operations (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-105.042	/	2.038
	=	-5,154.17 %

Humacyte's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin	=	Cash Flow from Operations (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-25.104	/	0.495
	=	-5,071.52 %

Frequently Asked Questions Learn more about OCF Margin % →

What does a OCF Margin % of -5,071.52% mean?

Humacyte (HUMA) has a OCF Margin % of -5,071.52% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Humacyte and its competitors. According to the industry distribution chart, Humacyte ranks #876 out of 960 companies in the Biotechnology industry, placing it in the top 91.2%.

Is Humacyte's OCF Margin % too high?

Humacyte's current OCF Margin % is -5,071.52%. Based on the distribution chart, Humacyte ranks #876 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Humacyte has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.

How does Humacyte's OCF Margin % compare to ZNTL and AVXL?

According to the Biotechnology industry distribution chart, Humacyte ranks #876 out of 960 companies for OCF Margin %. This places Humacyte in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good OCF Margin % for a Biotechnology company?

A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high OCF Margin % mean?

A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Humacyte and its competitors. Humacyte's current OCF Margin % is -5,071.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Humacyte stock overvalued right now?

Humacyte (HUMA) has a current OCF Margin % of -5,071.52%. The current OCF Margin % is -5,071.52%. Humacyte's overall GF Score™ is 21/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is OCF Margin % calculated?

OCF Margin % is calculated from a company's financial statements. For Humacyte (HUMA), the current OCF Margin % is -5,071.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Humacyte Business Description

Industry Healthcare Biotechnology

Comparable Companies ZNTL AVXL ELDN SABS ARMP TRDA SRZN ACIU NAGE MGNX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 2525 East North Carolina Highway 54, Durham, NC, USA, 27713

Website https://www.humacyte.com

Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

21GF Score

Get the complete analysis for HUMA

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.68

Price

View HUMA Analysis

See OCF Margin % data for all stocks →